The Danish pharmaceutical group Novo Nordisk intends to collaborate more closely with companies in the multi-billion dollar market for weight-loss medications in the United States. According to Chief Financial Officer Karsten Munk Knudsen, the company is finalizing direct agreements with employers in the US. These agreements involve various companies that wish to offer partial reimbursement for anti-obesity medications. Under such contracts, companies could subsidize or cover the cost of anti-obesity medications for their employees as a supplementary employment benefit.